Wu Zhulin, He Li, Wang Lianan, Peng Lisheng
The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen 518033, China.
Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China.
Evid Based Complement Alternat Med. 2020 Sep 15;2020:2396569. doi: 10.1155/2020/2396569. eCollection 2020.
Chinese herbs play a positive role in the management of hepatocellular carcinoma (HCC) in China. However, it is not clear which of Chinese herbs are critical for the treatment of HCC. Besides, mechanisms of CCHs in the treatment of HCC remain unclear. Hence, our goal is to identify the core Chinese herbs (CCHs) for treating HCC and explore their antitumor mechanism.
Firstly, clinical traditional Chinese medicine (TCM) prescriptions for HCC were collected from Chinese National Knowledge Infrastructure (CNKI) database, and then, data mining software was used to identify CCHs. After that, bioactive compounds and corresponding target genes of CCHs were obtained using three TCM databases, and target genes of HCC were acquired from MalaCards and OMIM. Subsequently, common target genes of CCHs and HCC were screened. Moreover, biological functions and pathways were analyzed, and Cytoscape plugin cytoHubba was used to identify hub genes. Finally, prognostic values of hub genes were verified by survival analysis, and the molecular docking approach was utilized to validate the interactions between targets and bioactive compounds of CCHs.
Eight CCHs were determined from 630 prescriptions, and 100 bioactive compounds (e.g., quercetin and luteolin) and 126 common target genes were screened. Furthermore, common target genes of CCHs and HCC were mainly enriched in cancer-associated pathways, and six hub genes with statistical significance in survival analysis were selected as key target genes for molecular docking. Additionally, molecular docking showed that the bioactive compounds docked well with the protein receptors of key target genes.
By combining data mining, network pharmacology, molecular docking, and survival analysis methods, we found that CCHs may play a therapeutic role in HCC through regulating the target genes and pathways related to cancer occurrence and development, angiogenesis, metastasis, and prognosis.
中药在中国肝细胞癌(HCC)的治疗中发挥着积极作用。然而,尚不清楚哪些中药对HCC治疗至关重要。此外,中药复方治疗HCC的机制仍不明确。因此,我们的目标是确定治疗HCC的核心中药,并探索其抗肿瘤机制。
首先,从中国知网数据库收集HCC的临床中医处方,然后使用数据挖掘软件识别核心中药。之后,利用三个中药数据库获取核心中药的生物活性成分和相应的靶基因,并从MalaCards和OMIM获取HCC的靶基因。随后,筛选核心中药和HCC的共同靶基因。此外,分析生物学功能和信号通路,并使用Cytoscape插件cytoHubba识别枢纽基因。最后,通过生存分析验证枢纽基因的预后价值,并利用分子对接方法验证核心中药的靶标与生物活性成分之间的相互作用。
从630个处方中确定了8种核心中药,筛选出100种生物活性成分(如槲皮素和木犀草素)和126个共同靶基因。此外,核心中药和HCC的共同靶基因主要富集在癌症相关通路中,在生存分析中有统计学意义的6个枢纽基因被选为分子对接的关键靶基因。此外,分子对接显示生物活性成分与关键靶基因的蛋白质受体对接良好。
通过结合数据挖掘、网络药理学、分子对接和生存分析方法,我们发现核心中药可能通过调节与癌症发生发展、血管生成、转移和预后相关的靶基因和信号通路在HCC治疗中发挥作用。